The Metabolic and Molecular Bases of Inherited Disease, pp.2753-2787, 2001. ,
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction, JAMA, vol.301, issue.22, pp.2331-2339, 2009. ,
DOI : 10.1001/jama.2009.801
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, vol.302, pp.412-423, 2009. ,
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease, New England Journal of Medicine, vol.361, issue.26, pp.2518-2528, 2009. ,
DOI : 10.1056/NEJMoa0902604
Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN), American Heart Journal, vol.149, issue.6 ,
DOI : 10.1016/j.ahj.2004.08.027
Is Lipoprotein(a) an Independent Risk Factor for Ischemic Heart Disease in Men? The Quebec Cardiovascular Study, Journal of the American College of Cardiology, vol.31, issue.3, pp.519-525, 1998. ,
DOI : 10.1016/S0735-1097(97)00528-7
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study, Atherosclerosis, vol.163, issue.2, pp.377-384, 2002. ,
DOI : 10.1016/S0021-9150(02)00026-6
Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women, JAMA, vol.296, pp.1363-1370, 2006. ,
Lipoprotein(a) and Coronary Heart Disease : Meta-Analysis of Prospective Studies, Circulation, vol.102, issue.10, pp.1082-1085, 2000. ,
DOI : 10.1161/01.CIR.102.10.1082
Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease<subtitle>Large-Scale Prospective Data</subtitle>, Archives of Internal Medicine, vol.168, issue.6, pp.598-608, 2008. ,
DOI : 10.1001/archinte.168.6.598
Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study, Circulation, vol.117, issue.2, pp.176-184, 2008. ,
DOI : 10.1161/CIRCULATIONAHA.107.715698
Mendelian randomization: prospects, potentials, and limitations, International Journal of Epidemiology, vol.33, issue.1, pp.30-42, 2004. ,
DOI : 10.1093/ije/dyh132
URL : http://ije.oxfordjournals.org/cgi/content/short/33/1/30
Familial hypercholesterolemia The Metabolic and Molecular Bases of Inherited Disease, pp.2863-2913, 2001. ,
Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease, New England Journal of Medicine, vol.338, issue.22, pp.1577-1584, 1998. ,
DOI : 10.1056/NEJM199805283382203
A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.27, issue.9, pp.2030-2036, 2007. ,
DOI : 10.1161/ATVBAHA.107.141291
Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia, Clinical Chemistry, vol.51, issue.11, pp.2067-2073, 2005. ,
DOI : 10.1373/clinchem.2005.055228
The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate., Journal of Clinical Investigation, vol.93, issue.6, pp.2758-2763, 1994. ,
DOI : 10.1172/JCI117292
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity, Current Opinion in Lipidology, vol.15, issue.2, pp.167-174, 2004. ,
DOI : 10.1097/00041433-200404000-00009
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions, Clinical Chemistry, vol.49, issue.11, pp.1785-1796, 2003. ,
DOI : 10.1373/clinchem.2003.023689
Lipoprotein(a) In: Ballantyne C, ed. Clinical Lipidology: A Companion to Braunwauld's Heart Disease, pp.130-143, 2009. ,
Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux, Atherosclerosis, vol.143, issue.2, pp.229-243, 1999. ,
DOI : 10.1016/S0021-9150(99)00064-7
Proteoglycans Contribution to Association of Lp(a) and LDL With Smooth Muscle Cell Extracellular Matrix, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.19, issue.5, pp.1162-1167, 1999. ,
DOI : 10.1161/01.ATV.19.5.1162
Defensin promotes the binding of lipoprotein(a) to vascular matrix, Blood, vol.94, pp.2007-2019, 1999. ,
Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice., Journal of Clinical Investigation, vol.100, issue.3, pp.558-564, 1997. ,
DOI : 10.1172/JCI119565
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin, The FASEB Journal, vol.20, pp.559-561, 2006. ,
DOI : 10.1096/fj.05-4857fje
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease, New England Journal of Medicine, vol.353, issue.1, pp.46-57, 2005. ,
DOI : 10.1056/NEJMoa043175
New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis and Cardiovascular Disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.27, issue.10, pp.2094-2099, 2007. ,
DOI : 10.1161/01.ATV.0000280571.28102.d4
Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue- type plasminogen activator. In vitro studies in a plasma milieu, vitro studies in a plasma milieu, pp.629-638, 1991. ,
DOI : 10.1161/01.ATV.11.3.629
Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation, Journal of Thrombosis and Haemostasis, vol.276, issue.12, pp.2113-2120, 2008. ,
DOI : 10.1111/j.1538-7836.2008.03183.x
The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis, Thrombosis and Haemostasis, vol.92, pp.495-502, 2004. ,
DOI : 10.1160/TH04-01-0006
Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?, Blood, vol.82, pp.392-397, 1993. ,
Apolipoprotein (a) Isoforms and the Risk of Vascular Disease: A Systematic Review of 40 Studies Involving 58,000 Participants, Journal of Vascular Surgery, vol.54, issue.1, pp.2160-2167, 2010. ,
DOI : 10.1016/j.jvs.2011.05.035
Role of Lipoprotein(a) and Apolipoprotein(a) Phenotype in Atherogenesis : Prospective Results From the Bruneck Study, Circulation, vol.100, issue.11, pp.1154-1160, 1999. ,
DOI : 10.1161/01.CIR.100.11.1154
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk, Journal of the American College of Cardiology, vol.37, issue.2, pp.434-439, 2001. ,
DOI : 10.1016/S0735-1097(00)01126-8
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary, Atherosclerosis, vol.194, issue.1, pp.2375-2414, 2007. ,
DOI : 10.1016/j.atherosclerosis.2007.08.024
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.24, issue.8, pp.149-161, 2004. ,
DOI : 10.1161/01.ATV.0000133317.49796.0E
Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere, Current Opinion in Lipidology, vol.20, issue.5, pp.393-401, 2009. ,
DOI : 10.1097/MOL.0b013e3283307bfe
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis, Atherosclerosis, vol.210, issue.2, pp.353-361, 2010. ,
DOI : 10.1016/j.atherosclerosis.2009.12.023
Reduction in mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid, Acta Med Scand, vol.233, pp.405-418, 1988. ,
Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin, Journal of the American College of Cardiology, vol.8, issue.6, pp.1245-1255, 1986. ,
DOI : 10.1016/S0735-1097(86)80293-5
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up, JAMA: The Journal of the American Medical Association, vol.264, issue.23, pp.3013-3017, 1990. ,
DOI : 10.1001/jama.264.23.3013
Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B, New England Journal of Medicine, vol.323, issue.19, pp.1289-1298, 1990. ,
DOI : 10.1056/NEJM199011083231901
Extended-Release Niacin or Ezetimibe and Carotid Intima???Media Thickness, New England Journal of Medicine, vol.361, issue.22, pp.2113-2122, 2009. ,
DOI : 10.1056/NEJMoa0907569
Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk, Pharmacology & Therapeutics, vol.126, issue.3, pp.314-345, 2010. ,
DOI : 10.1016/j.pharmthera.2010.01.008
Lipoprotein a: where are we now?, Current Opinion in Cardiology, vol.24, issue.4, pp.351-357, 2009. ,
DOI : 10.1097/HCO.0b013e32832ac21a
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk, Atherosclerosis, vol.164, issue.2, pp.305-311, 2002. ,
DOI : 10.1016/S0021-9150(02)00072-2
Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events, J Am Coll Cardiol, vol.52, pp.124-131, 2008. ,
Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a), JAMA: The Journal of the American Medical Association, vol.274, issue.22, pp.1771-1774, 1995. ,
DOI : 10.1001/jama.1995.03530220037029
Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice, Circulation, vol.118, issue.7, pp.743-753, 2008. ,
DOI : 10.1161/CIRCULATIONAHA.108.786822
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia, New England Journal of Medicine, vol.362, issue.10, pp.906-916, 2010. ,
DOI : 10.1056/NEJMoa0905633
Recommendations for the use of LDL apheresis, Atherosclerosis, vol.198, issue.2, pp.247-255, 2008. ,
DOI : 10.1016/j.atherosclerosis.2008.02.009